RecruitingNot ApplicableNCT06609941

Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

Sponsor

Foundation University Islamabad

Enrollment

32 participants

Start Date

Jun 18, 2024

Study Type

INTERVENTIONAL

Conditions

Bronchial Asthma

Summary

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether an ancient breathing technique called alternate nostril breathing (a form of yogic breathing that involves breathing through one nostril at a time) can help people with asthma breathe more easily when added on top of their regular medications. Researchers will measure how it affects shortness of breath and a breathing measurement called control pause. **You may be eligible if...** - You are between 18 and 45 years old - You have been diagnosed with mild persistent, moderate persistent, or intermittent asthma - You experience shortness of breath (graded 1–4 on a standard scale) **You may NOT be eligible if...** - You are having a severe asthma attack or a COPD flare-up - You have an active infection - You are unable to follow instructions - Your control pause (a breathing test) is already very good (over 40 seconds) - Your asthma is critically severe (peak flow rate below 50%) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAlternative nostril breathing

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

DRUGPharmacological therapy

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example: Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc. Week 01 and week 02: Patients will receive medication prescribed by pulmonologist. Week 03 and week 04: Patients will receive medication prescribed by pulmonologist.